Johannes Nemeth

Johannes Nemeth

Auto-generated profile, based on publicly available information

Johannes Nemeth

University Hospital Zürich

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2010 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MSMartina Sester
Martina Sester
Giovanni SotgiuGiovanni Sotgiu
Giovanni Sotgiu
CLChristoph Lange
Christoph Lange
CGC. Giehl
C. Giehl
EGEnrico Girardi
Enrico Girardi
DMD. Manissero
D. Manissero
Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent infection withMycobacterium tuberculosisin many countries. However, the role of IGRAs for the diagnosis of active tuberculosis (TB) remains unclear.Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) and quality assessment of diagnostic accuracy studies (QUADAS) guidelines, we searched PubMed, EMBASE and Cochrane databases to identify studies published in January 2001–November 2009 that evaluated the evidence of using QuantiFERON-TB® Gold in-tube (QFT-G-IT) and T-SPOT.TB®directly on blood or extrasanguinous specimens for the diagnosis of active TB.The literature search yielded 844 studies and 27 met the inclusion criteria. In blood and extrasanguinous fluids, the pooled sensitivity for the diagnosis of active TB was 80% (95% CI 75–84%) and 48% (95% CI 39–58%) for QFT-G-IT, and 81% (95% CI 78–84%) and 88% (confirmed and unconfirmed cases) (95% CI 82–92%) for T-SPOT.TB®, respectively. In blood and extrasanguinous fluids, the pooled specificity was 79% (95% CI 75–82%) and 82% (95% CI 70–91%) for QFT-G-IT, and 59% (95% CI 56–62%) and 82% (95% CI 78–86%) for T-SPOT.TB®, respectively.Although the diagnostic sensitivities of both IGRAs were higher than that of tuberculin skin tests, it was still not high enough to use as a rule out test for TB. Positive evidence for the use of IGRAs in compartments other than blood will require more independent and carefully designed prospective studies.

28 September 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
JNJohannes Nemeth
Johannes Nemeth
GOGabriela Oesch
Gabriela Oesch
SKStefan P. Kuster
Stefan P. Kuster
Antibiotics are commonly classified into bactericidal and bacteriostatic agents based on their antimicrobial action. We aimed to assess whether this distinction is clinically relevant. OVID MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL) and relevant references and conference proceedings using the Web of Science and Scopus databases were searched for randomized controlled trials comparing bactericidal with bacteriostatic antibiotics for treatment of severe infections. Main outcome measures were clinical cure rates and overall mortality. Abstracts of studies selected in the database search were screened by one reviewer; full-text screening and data extraction were performed by three independent reviewers. Thirty-three studies were included. Approximately half of patients were treated with bacteriostatic monotherapy. Infections covered were pneumonia (n=13), skin and soft tissue infections (n=8), intra-abdominal infections (n=4) and others (n=8). Neither clinical cure rates [risk ratio (RR), 0.99; 95% CI, 0.97-1.01; P=0.11] nor mortality rates (RR, 0.91; 95% CI, 0.76-1.08; P=0.28) were different between patients treated with bactericidal drugs and those treated with bacteriostatic drugs. Subgroup analyses showed a benefit for clinical cure rates associated with linezolid and increased mortality associated with tigecycline. In meta-regression, clinical cure rates remained higher in patients treated with linezolid (P=0.01); tigecycline displayed a close to significant association with increased mortality (P=0.05) if compared with other bacteriostatic agents. The categorization of antibiotics into bacteriostatic and bactericidal is unlikely to be relevant in clinical practice if used for abdominal infections, skin and soft tissue infections and pneumonia. Because we were not able to include studies on meningitis, endocarditis or neutropenia, no conclusion regarding these diseases can be drawn.

5 July 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
ARAlissa C. Rothchild
Alissa C. Rothchild
GOGregory S. Olson
Gregory S. Olson
JNJohannes Nemeth
Johannes Nemeth
LALynn M. Amon
Lynn M. Amon
DMDat Mai
Dat Mai
AAAlan Aderem
Alan Aderem
Alveolar macrophages (AMs) are the first cells to be infected during Mycobacterium tuberculosis (M.tb.) infection. Thus, the AM response to infection is the first of many steps leading to initiation of the adaptive immune response required for efficient control of infection. A hallmark of M.tb. infection is the slow initiation of the adaptive response, yet the mechanisms responsible for this are largely unknown. To study the initial AM response to infection, we developed a system to identify, sort, and analyze M.tb.-infected AMs from the lung within the first 10 days of infection. In contrast to what has been previously described using in vitro systems, M.tb.-infected AMs up-regulate a cell-protective antioxidant transcriptional signature that is dependent on the lung environment but not bacterial virulence. Computational approaches including pathway analysis and transcription factor motif enrichment analysis identify NRF2 as a master regulator of the response. Using knockout mouse models, we demonstrate that NRF2 drives expression of the cell-protective signature in AMs and impairs the control of early bacterial growth. AMs up-regulate a substantial pro-inflammatory response to M.tb. infection only 10 days after infection, yet comparisons with bystander AMs from the same infected animals demonstrate that M.tb.-infected AMs generate a less robust inflammatory response than the uninfected cells around them. Our findings demonstrate that the initial macrophage response to M.tb. in the lung is far less inflammatory than has previously been described by in vitro systems and may impede the overall host response to infection.

29 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAdrian Schmid
Adrian Schmid
AWAline Wolfensberger
Aline Wolfensberger
JNJohannes Nemeth
Johannes Nemeth
PSPeter W. Schreiber
Peter W. Schreiber
HSHugo Sax
Hugo Sax
SKStefan P. Kuster
Stefan P. Kuster
Infections caused by carbapenemase-producing, multidrug-resistant (MDR), or extensively drug-resistant (XDR) Gram-negative bacteria constitute a major therapeutic challenge. Whether combination antibiotic therapy is superior to monotherapy remains unknown. In this systematic review and meta-analysis OVID MEDLINE, EMBASE, PubMed, The Cochrane Library, and Scopus databases were searched for randomized controlled trials (RCTs) and observational studies published by December 2016 comparing mono- with combination antibiotic therapy for infections with carbapenemase-producing, MDR, or XDR Gram-negative bacteria. Mortality and clinical cure rates served as primary and secondary outcome measures, respectively. Of 8847 initially identified studies, 53 studies – covering pneumonia (n = 10 studies), blood stream (n = 15), osteoarticular (n = 1), and mixed infections (n = 27) - were included. 41% (n = 1848) of patients underwent monotherapy, and 59% (n = 2666) combination therapy. In case series/cohort studies (n = 45) mortality was lower with combination- vs. monotherapy (RR 0.83, CI 0.73–0.93, p = 0.002, I2 = 24%). Subgroup analysis revealed lower mortality with combination therapy with at least two in-vitro active antibiotics, in blood stream infections, and carbapenemase-producing Enterobacteriaceae. No mortality difference was seen in case-control studies (n = 6) and RCTs (n = 2). Cure rates did not differ regardless of study type. The two included RCTs had a high and unknown risk of bias, respectively. 16.7% (1/6) of case-control studies and 37.8% (17/45) of cases series/cohort studies were of good quality, whereas quality was poor in the remaining studies. In conclusion, combination antimicrobial therapy of multidrug-resistant Gram-negative bacteria appears to be superior to monotherapy with regard to mortality.

15 September 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
Michael RamharterMichael Ramharter
Michael Ramharter
FKFlorian Kurth
Florian Kurth
ASAnnette C. Schreier
Annette C. Schreier
JNJohannes Nemeth
Johannes Nemeth
IGIsabelle von Glasenapp
Isabelle von Glasenapp
PKPeter G. Kremsner
Peter G. Kremsner
Background. The development of novel artemisinin-combination therapies suitable for the treatment of pediatric patients suffering from malaria is a research priority. The aim of this study was to investigate a novel fixed-dose pyronaridine-artesunate combination for the treatment of uncomplicated falciparum malaria in Gabonese patients 2–14 years old. Methods. The study was designed as an open-label dose-escalation study recruiting 60 pediatric patients sequentially in 4 treatment cohorts: study drugs were administered once daily for 3 days, as tablet coformulations (pyronaridine: artesunate ratios of 6:2, 9:3, and 12:4 mg/kg) and as a granule coformulation (pyronaridine:artesunate ratio of 9:3 mg/kg). The primary end points were tolerability, safety, and pharmacokinetics of pyronaridine-artesunate treatment. Efficacy was treated as a secondary outcome measure. Results. The drugs had a good tolerability and safety profile, at all dose levels. Pharmacokinetic analysis revealed a dose-dependent increase in the maximum plasma/blood concentration and the area under the curve, as well as comparable relative bioavailability for the granule coformulation. Polymerase chain reaction—corrected cure rates at day 28 were 100% in per-protocol analysis, at all dose levels. Conclusions. Pyronaridine-artesunate is a promising novel artemisinin-combination therapy for pediatric patients with uncomplicated Plasmodium falciparum malaria, and the development of both the tablet and the granule coformulations is warranted. Trial Registration. Clinical Trials.gov identifier NCT00331136.

16 July 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JNJohannes Nemeth
Johannes Nemeth
GOGregory S. Olson
Gregory S. Olson
ARAlissa C. Rothchild
Alissa C. Rothchild
AJAna N. Jahn
Ana N. Jahn
DMDat Mai
Dat Mai
ADAlan H. Diercks
Alan H. Diercks
Progress in tuberculosis vaccine development is hampered by an incomplete understanding of the immune mechanisms that protect against infection with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis. Although the M72/ASOE1 trial yielded encouraging results (54% efficacy in subjects with prior exposure to Mtb), a highly effective vaccine against adult tuberculosis remains elusive. We show that in a mouse model, establishment of a contained and persistent yet non-pathogenic infection with Mtb (“contained Mtb infection”, CMTB) rapidly and durably reduces tuberculosis disease burden after re-exposure through aerosol challenge. Protection is associated with elevated activation of alveolar macrophages, the first cells that respond to inhaled Mtb, and accelerated recruitment of Mtb-specific T cells to the lung parenchyma. Systems approaches, as well as ex vivo functional assays and in vivo infection experiments, demonstrate that CMTB reconfigures tissue resident alveolar macrophages via low grade interferon-γ exposure. These studies demonstrate that under certain circumstances, the continuous interaction of the immune system with Mtb is beneficial to the host by maintaining elevated innate immune responses. Paradoxically, although tuberculosis (TB) ranks as the deadliest infectious disease world-wide, the immune mechanisms that protect against the disease are quite effective: Despite a high prevalence of infection with Mycobacterium tuberculosis (Mtb), the vast majority of individuals with an intact immune system contain the infection indefinitely with no clinical symptoms. Historical cohort studies and contemporary epidemiological studies indicate that prior infection with Mtb is actually protective against the development of active TB after re-exposure. Understanding the mechanisms underlying this natural protection would inform vaccine design efforts, however progress has been hampered by the lack of a small animal model of the protective effects of contained Mtb infection (CMTB). Previously, the protective effects have been attributed to adaptive immune responses. This study shows that CMTB also affects the innate immune response and is associated with low-level interferon-γ cytokinemia. While experiments in mice have elucidated many of the fundamental mechanisms underlying the immune response to Mtb, a small-animal model for the protective effect of CMTB, a critical feature of the human disease, has been elusive. Here, we demonstrate a mouse model that can enable mechanistic studies of the well-established but poorly understood role of CMTB in protection against re-infection.